Polycystic ovary syndrome in men: Stein-Leventhal syndrome revisited

Medical Hypotheses

Volumn 68, Issue 3, 2007, Pages 480-483

  Kurzrock, Razelle ^a   Cohen, Philip R ^b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIANDROGEN; CLOMIFENE; CONTRACEPTIVE AGENT; FINASTERIDE; FLUTAMIDE; INSULIN SENSITIZING AGENT; MEDROXYPROGESTERONE ACETATE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SPIRONOLACTONE; TROGLITAZONE;

ALOPECIA; ANOVULATION; ARTICLE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE COURSE; GENETIC SUSCEPTIBILITY; GLUCOSE TOLERANCE TEST; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN RESISTANCE; LABORATORY DIAGNOSIS; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE; STEIN LEVENTHAL SYNDROME;

FEMALE; HUMANS; MALE; POLYCYSTIC OVARY SYNDROME; SEX CHARACTERISTICS;

EID: 33845981087     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.03.057     Document Type: Article

References (20)

1. Stein I.L., and Leventhal M.L. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29 (1935) 181-191
2. Knochenhauer E.S., Key T.J., Kahsar-Miller M., Waggoner W., Boots L.R., and Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83 (1998) 3078-3082
3. Futterwelt W. Polycystic ovary syndrome: clinical perspectives and management. Obstet Gynecol Surv 54 (1999) 403-413
4. Franks S. Assessment and management of anovulatory infertility in polycystic ovary syndrome. Endocrinol Metab Clin North Am 32 (2003) 639-651
5. Richardson M.R. Current perspectives in polycystic ovary syndrome. Am Fam Physician 68 (2003) 697-704
6. Rotterdam ESHRE/ASRM-Sponsored PCOS Concensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
7. Laven J.S., Imani B., Eijkemans M.J., and Fauser B.C. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv 57 (2002) 755-767
8. O'Driscoll J.B., Mamtora H., Higginson J., Pollock A., Kane J., and Anderson D.C. A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia. Clin Endocrinol 41 (1994) 231-236
9. Polson D.W., Adams J., Wadsworth J., and Franks S. Polycystic ovaries-a common finding in normal women. Lancet 1 8590 (1988) 870-872
10. Tsilchorozidou T., Overton C., and Conway G.S. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol 60 (2004) 1-17
11. Dunaif A., Xia J., Book C.B., Schenker E., and Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 96 (1995) 801-810
12. Book C.B., and Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 84 (1999) 3110-3116
13. Yilmaz M., Bukan N., Ersoy R., Karakoc A., Yetkin I., Ayvaz G., et al. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. Hum Reprod 20 (2005) 2414-2420
14. Govind A., Obhrai M.S., and Clayton R.N. Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. J Clin Endocrinol Metab 84 (1999) 38-43
15. Benitez R., Sir-Petermann T., Palomino A., Angel B., Maliqueo M., Perez F., et al. Prevalence of metabolic disorders among family members of patients with polycystic ovary syndrome. Rev Med Chil 129 (2001) 707-712
16. Stout D.L., and Fugate S.E. Thiazolidinediones for treatment of polycystic ovary syndrome. Pharmacotherapy 25 (2005) 244-252
17. Velazquez E.M., Mendoza S., Hamer T., Sosa F., and Glueck C.J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43 (1994) 647-654
18. Lord J.M., Flight I.H., and Norman R.J. Metformin in polycystic ovary syndrome systematic review and meta-analysis. BMJ 327 (2003) 951-953
19. Harborne L., Fleming R., Lyall H., Sattar N., and Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 4116-4123
20. Legro R.S., Finegood D., and Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 83 (1998) 2694-2698